Dennis Wright - REALORD GRP Insider

CUV -- Germany Stock  

EUR 0.49  0.011  2.29%

Dr. Dennis J. Wright, BPharm, MSc, Ph.D., is Acting Chief Scientific Officer of Clinuvel Pharmaceuticals Ltd since September 2012. He was previously Vice President Scientific Affairs of the Company. Dr. Wright has a range of experience in the pharmaceutical industry spanning 25 years. He spent more than 17 years at CSL working predominantly in regulatory affairs with nearly a decade as Regulatory Affairs Manager. Most recently he was Global Pharmacovigilance Manager and Regulatory Affairs Manager for the Australian and New Zealand operations of Mayne Pharma, a company recently acquired by Halcygen . He has a Pharmacy degree and postgraduate qualifications from University of Sydney and Health Economics qualifications from Monash University, Melbourne
  Executive Since 2012      
Wright is responsible for the clinical and regulatory development team and progressing afamelanotide through to regulatory approval in global markets.

Management Efficiency

Entity Summary

REALORD GRP HLDGS HD 10 (CUV) is traded on Berlin Stock Exchange in Germany. and employs 8 people.


Willem Blijdorp, Non-Executive Director
Elie Ishag, Non-Executive Independent Director
Stanley McLiesh, Non-Executive Independent Chairman of the Board
Philippe Wolgen, CEO, Managing Director, Director
Darren Keamy, Company Secretary, CFO
Dennis Wright, Acting Chief Scientific Officer
Brenda Shanahan, Non-Executive Independent Director

Stock Performance Indicators

Current Sentiment - CUV

REALORD GRP HLDGS Investor Sentiment
Macroaxis portfolio users are unresponsive in their opinion about investing in REALORD GRP HLDGS HD 10. What is your perspective on investing in REALORD GRP HLDGS HD 10? Are you bullish or bearish?
50% Bullish
50% Bearish

Pair Correlation

Equities Pair Trading Analysis
Correlation analysis and pair trading evaluation for REALORD GRP and Steris Plc. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Check also Trending Equities. Please also try Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.